Prikaz rezultata 1 – 5 od 5 za pretragu 'Stephenie D. Prokopec (16797700)', vrijeme upita: 0,01s Detaljiziraj rezultate
  1. 1
    Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... od Stephanie Lheureux (16797697)

    Izdano 2025
    Daljnji autori: “…Stephenie D. Prokopec (16797700)…”
    Spremi u popis
    Spremljeno u:
  2. 2
    Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... od Stephanie Lheureux (16797697)

    Izdano 2025
    Daljnji autori: “…Stephenie D. Prokopec (16797700)…”
    Spremi u popis
    Spremljeno u:
  3. 3
    Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... od Stephanie Lheureux (16797697)

    Izdano 2025
    Daljnji autori: “…Stephenie D. Prokopec (16797700)…”
    Spremi u popis
    Spremljeno u:
  4. 4
    Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... od Stephanie Lheureux (16797697)

    Izdano 2025
    Daljnji autori: “…Stephenie D. Prokopec (16797700)…”
    Spremi u popis
    Spremljeno u:
  5. 5
    Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... od Stephanie Lheureux (16797697)

    Izdano 2025
    Daljnji autori: “…Stephenie D. Prokopec (16797700)…”
    Spremi u popis
    Spremljeno u:

Alati za pretragu: